Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

صناعة

Biotechnology

قطاع

Healthcare

المقر الرئيسي

GB

المدير التنفيذي

Kevin Lee

المدرجة منذ ذلك الحين

23 مايو 2019

موظفين

288

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

صناعة

Biotechnology

قطاع

Healthcare

المقر الرئيسي

GB

المدير التنفيذي

Kevin Lee

المدرجة منذ ذلك الحين

23 مايو 2019

موظفين

288